Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis

Anemia is a common symptom of hematological malignancies and red blood cell (RBC) transfusion is the primary supportive treatment, with many patients becoming transfusion dependent. Hemanext Inc. (Lexington, MA, United States) has developed a CE mark certified device to process and store RBCs hypoxically – citrate-phosphatedextrose (CPD)/phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) RBCs, leukocytes-reduced (LR), O2/CO2 reduced – with the aim of improving RBC quality for transfusion.

Source: Transfusion and Apheresis Science - June 21, 2023 Category: Hematology Authors: H åkon Reikvam, Geir Hetland, Farshid Ezligini, Kim Dorsch, Laurel Omert, Andrew Dunham, Stian K Almeland Source Type: research